MacroGenics Announces Date of Third Quarter 2022 Financial Results Conference Call
MacroGenics, Inc. (Nasdaq: MGNX) announced it will release its third-quarter 2022 financial results on November 3, 2022, after market close. A conference call to discuss these results and the company's recent corporate developments will follow at 4:30 PM ET on the same day. All interested participants are encouraged to register for the call via a provided link to receive confirmation details. MacroGenics continues to focus on developing innovative monoclonal antibody-based therapeutics for cancer treatment, leveraging its advanced technology platforms.
- Focus on developing monoclonal antibody-based therapeutics indicates strong commitment to innovation.
- Strategic collaborations with global pharmaceutical companies enhance growth potential.
- No specific financial data or insights into current product pipeline, which may raise concerns among investors.
ROCKVILLE, MD, Oct. 26, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the third quarter of 2022 after the market closes on Thursday, November 3, 2022. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursday, November 3, 2022, at 4:30 pm ET.
Conference Call Information
To participate via telephone, please register in advance via this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. The listen-only webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at http://ir.macrogenics.com/events.cfm. A recorded replay of the webcast will be available shortly after the conclusion of the call and archived on the Company's website for 30 days following the call.
About MacroGenics, Inc.
MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.
###
FAQ
When will MacroGenics announce its third-quarter 2022 financial results?
What time is the MacroGenics conference call on November 3, 2022?
How can I participate in the MacroGenics conference call?
What is the focus of MacroGenics as a company?
